• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ile254Val (c.760A>G); ClinVar=VCV000406605; Zygosity=Homozygous (PubMed=8089864).
  

PubMed=8089864; DOI=10.1093/jnci/86.19.1458
Fujiwara T., Cai D.-W., Georges R.N., Mukhopadhyay T., Grimm E.A., Roth J.A.
Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model.
J. Natl. Cancer Inst. 86:1458-1462(1994)

PubMed=7634243; DOI=10.1016/0304-3835(95)03845-N
Hwang C.-C., Fang K., Li L.-M., Shih S.H.
Insulin-like growth factor-I is an autocrine regulator for the brain metastatic variant of a human non-small cell lung cell line.
Cancer Lett. 94:157-163(1995)

PubMed=8528963
Cai D.-W., Mukhopadhyay T., Roth J.A.
Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA.
Cancer Gene Ther. 2:199-205(1995)

PubMed=8956792; DOI=10.1038/bjc.1996.629; PMCID=PMC2077222
Fang K.
An enhanced and sensitive autocrine stimulation by transforming growth factor-alpha is acquired in the brain metastatic variant of a human non-small-cell lung cancer cell line.
Br. J. Cancer 74:1776-1782(1996)

PubMed=9498829; DOI=10.1007/s004320050127
Perdomo J.A., Naomoto Y., Haisa M., Fujiwara T., Hamada M., Yasuoka Y., Tanaka N.
In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer.
J. Cancer Res. Clin. Oncol. 124:10-18(1998)